parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	group enriched, including oligodendrocytes; strongest in myonuclei	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	4 Parkinson's papers of 163	0.79
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 10354

CTNNA3 in dopamine neurons, braak-0.29 (p 0.449) → +0.75 (p 0.021)receipt 10396
CTNNA3 in oligodendrocytes, braak+0.36 (p 0.344) → +0.04 (p 0.927)receipt 10395

receipt 10396: CTNNA3 in dopamine neurons, braak

power: full sample +0.28 (p 0.269, n 18), 95% CI -0.22 to +0.66. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.23 (p 0.351, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.27 (p 0.281, n 18). could be the mix.
skeptic: leave-one-out range +0.18 to +0.42, sign flips 0; without severely affected donors +0.28 (p 0.269, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CTNNA3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 10395: CTNNA3 in oligodendrocytes, braak

power: full sample +0.37 (p 0.130, n 18), 95% CI -0.12 to +0.71. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.39 (p 0.114, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.51 (p 0.032, n 18). not the mix.
skeptic: leave-one-out range +0.29 to +0.55, sign flips 0; without severely affected donors +0.37 (p 0.130, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CTNNA3 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts